$TCRT
Alaunos Therapeutics, Inc. Stock $tcrt

$tcrt Overview Financials Valuation SEC Filings Company Website

2014 Q1 Form 10-K Financial Statement

#000119312514080282 Filed on March 03, 2014

Income Statement

Concept	2014 Q1	2013 Q4	2013 Q3
Revenue	$200.0K	$200.0K	$200.0K
YoY Change	0.0%	0.0%	0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.440M	$4.200M	$3.070M
YoY Change	-26.34%	3.45%	-46.23%
% of Gross Profit
Research & Development	$6.542M	$2.720M	$6.247M
YoY Change	-65.77%	-92.22%	-61.47%
% of Gross Profit
Depreciation & Amortization	$120.0K	$160.0K	$180.0K
YoY Change	-40.0%	-15.79%	-10.0%
% of Gross Profit
Operating Expenses	$6.542M	$6.920M	$6.247M
YoY Change	-65.77%	-82.27%	-61.47%
Operating Profit	-$9.784M	-$6.719M	-$9.115M
YoY Change	-58.51%	-82.7%	-58.05%
Interest Expense	$80.00K	-$1.790M	-$7.410M
YoY Change	-99.26%	-120.89%	-287.59%
% of Operating Profit
Other Income/Expense, Net	-$9.000K	-$390.0K	-$191.0K
YoY Change	125.0%	-880.0%	354.76%
Pretax Income	-$9.710M	-$8.900M	-$16.71M
YoY Change	-24.14%	-70.56%	-6.23%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$9.711M	-$8.903M	-$16.71M
YoY Change	-24.13%	-70.54%	-6.23%
Net Earnings / Revenue	-4855.5%	-4451.5%	-8356.5%
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.10	-$0.09	-$0.20
COMMON SHARES
Basic Shares Outstanding	100.6M shares	83.70M shares	83.52M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q1	2013 Q4	2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$60.40M	$68.20M	$23.60M
YoY Change	8.44%	-6.96%	-75.24%
Cash & Equivalents	$60.39M	$68.20M	$23.63M
Short-Term Investments
Other Short-Term Assets	$1.600M	$1.900M	$3.200M
YoY Change	-66.67%	-72.46%	-55.56%
Inventory
Prepaid Expenses
Receivables	$0.00	$100.0K	$400.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$62.00M	$70.30M	$27.28M
YoY Change	2.38%	-12.43%	-73.42%
LONG-TERM ASSETS
Property, Plant & Equipment	$679.0K	$801.0K	$1.336M
YoY Change	-64.43%	-59.83%	-36.38%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$517.0K	$528.0K	$739.0K
YoY Change	-30.42%	-47.25%	-26.1%
Total Long-Term Assets	$1.324M	$1.457M	$2.203M
YoY Change	-52.46%	-53.42%	-26.57%
TOTAL ASSETS
Total Short-Term Assets	$62.00M	$70.30M	$27.28M
Total Long-Term Assets	$1.324M	$1.457M	$2.203M
Total Assets	$63.33M	$71.75M	$29.48M
YoY Change	-0.03%	-13.97%	-72.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$578.0K	$422.0K	$891.0K
YoY Change	-41.2%	-72.03%	-78.79%
Accrued Expenses	$5.752M	$6.357M	$11.57M
YoY Change	-68.94%	-61.51%	-30.7%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$7.354M	$7.791M	$13.36M
YoY Change	-63.88%	-58.7%	-38.42%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$20.00K	$20.00K	$20.00K
YoY Change	-99.08%		-99.92%
Total Long-Term Liabilities	$20.00K	$20.00K	$20.00K
YoY Change	-99.08%		-99.92%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.354M	$7.791M	$13.36M
Total Long-Term Liabilities	$20.00K	$20.00K	$20.00K
Total Liabilities	$21.59M	$22.37M	$25.85M
YoY Change	-15.17%	-36.01%	-44.53%
SHAREHOLDERS EQUITY
Retained Earnings		-$340.8M
YoY Change		20.14%
Common Stock	$388.7M	$386.6M	$331.9M
YoY Change	18.65%	18.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$41.73M	$49.38M	$3.631M
YoY Change
Total Liabilities & Shareholders Equity	$63.33M	$71.75M	$29.48M
YoY Change	-0.03%	-13.97%	-72.09%

Cashflow Statement

Concept	2014 Q1	2013 Q4	2013 Q3
OPERATING ACTIVITIES
Net Income	-$9.711M	-$8.903M	-$16.71M
YoY Change	-24.13%	-70.54%	-6.23%
Depreciation, Depletion And Amortization	$120.0K	$160.0K	$180.0K
YoY Change	-40.0%	-15.79%	-10.0%
Cash From Operating Activities	-$8.650M	-$9.050M	-$15.50M
YoY Change	-52.58%	-57.91%	5.44%
INVESTING ACTIVITIES
Capital Expenditures	$2.000K	$10.00K	$0.00
YoY Change	-98.25%	-87.5%	-100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change
Cash From Investing Activities	$0.00	-$10.00K	$0.00
YoY Change	-100.0%	-87.5%	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$132.0K	$57.60M
YoY Change	-46.34%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	840.0K	53.63M	200.0K
YoY Change	18.98%	-12017.78%	900.0%
NET CHANGE
Cash From Operating Activities	-8.650M	-9.050M	-15.50M
Cash From Investing Activities	0.000	-10.00K	0.000
Cash From Financing Activities	840.0K	53.63M	200.0K
Net Change In Cash	-7.810M	44.57M	-15.30M
YoY Change	-55.75%	-302.32%	1.66%
FREE CASH FLOW
Cash From Operating Activities	-$8.650M	-$9.050M	-$15.50M
Capital Expenditures	$2.000K	$10.00K	$0.00
Free Cash Flow	-$8.652M	-$9.060M	-$15.50M
YoY Change	-52.87%	-58.02%	2.85%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2004Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	9017538	shares
CY2004Q1	us-gaap	Share Price SharePrice	0.50
CY2006Q2	ziop	Common Stock Price Per Share1 CommonStockPricePerShare1	4.63
CY2006Q2	ziop	Class Of Warrant Or Right Fair Value Assumption Risk Free Interest Rate ClassOfWarrantOrRightFairValueAssumptionRiskFreeInterestRate	0.0501	pure
CY2006Q2	ziop	Class Of Warrant Or Right Fair Value Assumption Stock Volatility ClassOfWarrantOrRightFairValueAssumptionStockVolatility	1.00	pure
CY2006Q2	ziop	Class Of Warrant Or Right Fair Value Assumption Expected Dividend Yield ClassOfWarrantOrRightFairValueAssumptionExpectedDividendYield	0.00	pure
CY2007Q1	ziop	Common Stock Price Per Share1 CommonStockPricePerShare1	5.225
CY2007Q1	ziop	Class Of Warrant Or Right Fair Value Assumption Risk Free Interest Rate ClassOfWarrantOrRightFairValueAssumptionRiskFreeInterestRate	0.0471	pure
CY2007Q1	ziop	Class Of Warrant Or Right Fair Value Assumption Expected Life ClassOfWarrantOrRightFairValueAssumptionExpectedLife	5	Y
CY2007Q1	ziop	Class Of Warrant Term ClassOfWarrantTerm	P5Y
CY2007Q1	ziop	Class Of Warrant Or Right Fair Value Assumption Stock Volatility ClassOfWarrantOrRightFairValueAssumptionStockVolatility	0.93	pure
CY2007Q1	ziop	Class Of Warrant Or Right Fair Value Assumption Expected Dividend Yield ClassOfWarrantOrRightFairValueAssumptionExpectedDividendYield	0.00	pure
CY2007Q1	ziop	Exercise Price Of Warrants ExercisePriceOfWarrants	5.75
CY2010Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2010Q2	ziop	Investment Option Exercise Period InvestmentOptionExercisePeriod	P30D
CY2014Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	100556625	shares
CY2004Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2006Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2006Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2006Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2006Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	30000000	shares
CY2006Q2	ziop	Shares Authorized SharesAuthorized	280000000	shares
CY2005Q2	ziop	Commission Rate CommissionRate	0.07	pure
CY2010Q2	ziop	Common Stock Price Per Share1 CommonStockPricePerShare1	5.00
CY2003Q3	us-gaap	Stockholders Equity StockholdersEquity	500000
CY2003Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	0
CY2003Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1001949	shares
CY2003Q3	us-gaap	Share Price SharePrice	0.50
CY2005Q3	ziop	Percentage Of Outstanding Common Shares On Fully Diluted Basis PercentageOfOutstandingCommonSharesOnFullyDilutedBasis	0.968	pure
CY2009Q3	ziop	Common Stock Price Per Share1 CommonStockPricePerShare1	1.825
CY2010Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	348753	shares
CY2010Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.82
CY2010Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4566935	shares
CY2010Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	2.30
CY2010Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	275000
CY2010Q4	us-gaap	Stockholders Equity StockholdersEquity	30553000
CY2010Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	60392000
CY2011Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3636926	shares
CY2011Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2011Q1	ziop	Common Stock Price Per Share1 CommonStockPricePerShare1	4.80
CY2011Q1	ziop	Common Stock Price Per Share1 CommonStockPricePerShare1	5.75
CY2013Q2	dei	Entity Public Float EntityPublicFloat	141663241
CY2013Q4	ziop	Common Stock Price Per Share1 CommonStockPricePerShare1	3.50
CY2003Q4	us-gaap	Stockholders Equity StockholdersEquity	340000
CY2004Q4	ziop	Class Of Warrant Or Right Fair Value Assumption Risk Free Interest Rate ClassOfWarrantOrRightFairValueAssumptionRiskFreeInterestRate	0.0393	pure
CY2004Q4	ziop	Class Of Warrant Or Right Fair Value Assumption Expected Life ClassOfWarrantOrRightFairValueAssumptionExpectedLife	7	Y
CY2004Q4	ziop	Class Of Warrant Or Right Fair Value Assumption Stock Volatility ClassOfWarrantOrRightFairValueAssumptionStockVolatility	1.34	pure
CY2004Q4	ziop	Class Of Warrant Or Right Fair Value Assumption Expected Dividend Yield ClassOfWarrantOrRightFairValueAssumptionExpectedDividendYield	0.00	pure
CY2004Q4	us-gaap	Stockholders Equity StockholdersEquity	-144000
CY2004Q4	ziop	Class Of Warrant Or Right Fair Value Assumption Risk Free Interest Rate ClassOfWarrantOrRightFairValueAssumptionRiskFreeInterestRate	0.0393	pure
CY2004Q4	ziop	Class Of Warrant Or Right Fair Value Assumption Expected Life ClassOfWarrantOrRightFairValueAssumptionExpectedLife	7	Y
CY2004Q4	ziop	Class Of Warrant Or Right Fair Value Assumption Stock Volatility ClassOfWarrantOrRightFairValueAssumptionStockVolatility	1.34	pure
CY2004Q4	ziop	Class Of Warrant Or Right Fair Value Assumption Expected Dividend Yield ClassOfWarrantOrRightFairValueAssumptionExpectedDividendYield	0.00	pure
CY2005Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2005Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2005Q4	us-gaap	Stockholders Equity StockholdersEquity	7202000
CY2005Q4	ziop	Class Of Warrant Or Right Fair Value Assumption Risk Free Interest Rate ClassOfWarrantOrRightFairValueAssumptionRiskFreeInterestRate	0.0439	pure
CY2005Q4	ziop	Class Of Warrant Or Right Fair Value Assumption Expected Life ClassOfWarrantOrRightFairValueAssumptionExpectedLife	5	Y
CY2005Q4	ziop	Class Of Warrant Or Right Fair Value Assumption Stock Volatility ClassOfWarrantOrRightFairValueAssumptionStockVolatility	1.09	pure
CY2005Q4	ziop	Preferred Stock Conversion Rate PreferredStockConversionRate	0.500974	pure
CY2005Q4	ziop	Class Of Warrant Or Right Fair Value Assumption Expected Dividend Yield ClassOfWarrantOrRightFairValueAssumptionExpectedDividendYield	0.00	pure
CY2012Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	835000
CY2012Q4	us-gaap	Other Additional Capital OtherAdditionalCapital	6909000
CY2012Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	122343000
CY2006Q4	us-gaap	Stockholders Equity StockholdersEquity	26533000
CY2007Q4	us-gaap	Stockholders Equity StockholdersEquity	30370000
CY2008Q4	us-gaap	Stockholders Equity StockholdersEquity	6739000
CY2008Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	18866000
CY2008Q4	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	-83495000
CY2008Q4	ziop	Warrants Liability WarrantsLiability	72000
CY2009Q4	ziop	Common Stock Price Per Share1 CommonStockPricePerShare1	3.10
CY2009Q4	ziop	Warrants To Purchase Shares WarrantsToPurchaseShares	0.5	shares
CY2009Q4	ziop	Common Stock Price Per Share1 CommonStockPricePerShare1	3.10
CY2009Q4	us-gaap	New Accounting Pronouncement Or Change In Accounting Principle Cumulative Effect Of Change On Equity Or Net Assets1 NewAccountingPronouncementOrChangeInAccountingPrincipleCumulativeEffectOfChangeOnEquityOrNetAssets1	-72000
CY2009Q4	us-gaap	Stockholders Equity StockholdersEquity	28104000
CY2009Q4	ziop	Estimated Fair Value Of Warrant EstimatedFairValueOfWarrant	22900000
CY2009Q4	ziop	Class Of Warrant Or Right Fair Value Assumption Risk Free Interest Rate ClassOfWarrantOrRightFairValueAssumptionRiskFreeInterestRate	0.0214	pure
CY2009Q4	ziop	Class Of Warrant Or Right Fair Value Assumption Expected Life ClassOfWarrantOrRightFairValueAssumptionExpectedLife	5	Y
CY2009Q4	ziop	Class Of Warrant Term ClassOfWarrantTerm	P5Y
CY2009Q4	ziop	Class Of Warrant Or Right Fair Value Assumption Stock Volatility ClassOfWarrantOrRightFairValueAssumptionStockVolatility	1.05	pure
CY2009Q4	ziop	Class Of Warrant Or Right Fair Value Assumption Expected Dividend Yield ClassOfWarrantOrRightFairValueAssumptionExpectedDividendYield	0.00	pure
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	950906	shares
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.08
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5138486	shares
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	4.34
CY2011Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	275000
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	71607000
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	104713000
CY2012Q1	ziop	Common Stock Price Per Share1 CommonStockPricePerShare1	5.20
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	83236840	shares
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	733739	shares
CY2012Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3683786	shares
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.11
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7147303	shares
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	4.37
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.56
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	30000000	shares
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	83236840	shares
CY2012Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	2733000
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2012Q4	us-gaap	Other Employee Related Liabilities Current OtherEmployeeRelatedLiabilitiesCurrent	474000
CY2012Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	48445000
CY2012Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	325177000
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	18864000
CY2012Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	275000
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1924000
CY2012Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	903000
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1509000
CY2012Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	800000
CY2012Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	585000
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	16516000
CY2012Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	452000
CY2012Q4	us-gaap	Liabilities Liabilities	34959000
CY2012Q4	us-gaap	Deferred Rent Credit DeferredRentCredit	439000
CY2012Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	400000
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	83000
CY2012Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	39000
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	83404000
CY2012Q4	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	11000
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1001000
CY2012Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	42715000
CY2012Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	991000
CY2012Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	122343000
CY2012Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	133000
CY2012Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	1357000
CY2012Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet
CY2012Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3918000
CY2012Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	153000
CY2012Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	998000
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1994000
CY2012Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	72002000
CY2012Q4	us-gaap	Assets Assets	83404000
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	73306000
CY2012Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	18388000
CY2012Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	3972000
CY2012Q4	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	283724000
CY2012Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	856000
CY2012Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	1388000
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6912000
CY2012Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	58000
CY2012Q4	us-gaap	Assets Current AssetsCurrent	80276000
CY2012Q4	ziop	Accrued Consulting Fees Current AccruedConsultingFeesCurrent	9628000
CY2012Q4	ziop	Deferred Tax Assets Capitalized Acquisition Costs DeferredTaxAssetsCapitalizedAcquisitionCosts	13270000
CY2012Q4	ziop	Deferred Tax Assets Depreciation DeferredTaxAssetsDepreciation	331000
CY2012Q4	ziop	Accrued Manufacturing Costs Current AccruedManufacturingCostsCurrent	3217000
CY2012Q4	ziop	Deferred Tax Assets Start Up And Organizational Costs DeferredTaxAssetsStartUpAndOrganizationalCosts	44262000
CY2012Q4	ziop	Warrants Liability WarrantsLiability	12962000
CY2012Q4	ziop	Warrant Liabilities Fair Value Disclosure WarrantLiabilitiesFairValueDisclosure	12962000
CY2012Q4	ziop	Computer And Office Equipment Gross ComputerAndOfficeEquipmentGross	1552000
CY2012Q4	ziop	Accrued Preclinical Services Current AccruedPreclinicalServicesCurrent	411000
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	100159618	shares
CY2013Q4	ziop	Accrued Manufacturing Costs Current AccruedManufacturingCostsCurrent	547000
CY2013Q4	ziop	Deferred Tax Assets Start Up And Organizational Costs DeferredTaxAssetsStartUpAndOrganizationalCosts	41529000
CY2013Q4	ziop	Class Of Warrant Or Right Fair Value Assumption Stock Volatility ClassOfWarrantOrRightFairValueAssumptionStockVolatility	1.34	pure
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	352865	shares
CY2013Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	45823	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3471935	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.81
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6747303	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	416964	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	6711969	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	4.38
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Share Price SharePrice	3.50
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.01
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	10539767	shares
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	30000000	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	4.01
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	100159618	shares
CY2013Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	1933000
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	1196000
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7791000
CY2013Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	238000
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2153000
CY2013Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	230000
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	4354000
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	422000
CY2013Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	582000
CY2013Q4	us-gaap	Other Additional Capital OtherAdditionalCapital	3603000
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	501000
CY2013Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	148604000
CY2013Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	20000
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	49383000
CY2013Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	386511000
CY2013Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	800000
CY2013Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	255000
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6357000
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	1236000
CY2013Q4	us-gaap	Purchase Commitment Remaining Minimum Amount Committed PurchaseCommitmentRemainingMinimumAmountCommitted	19000000
CY2013Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	227000
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	424000
CY2013Q4	us-gaap	Liabilities Liabilities	22371000
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	997000
CY2013Q4	us-gaap	Deferred Rent Credit DeferredRentCredit	1100000
CY2013Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	851000
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	100000
CY2013Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	212000
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	71754000
CY2013Q4	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	252000
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	528000
CY2013Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	66209000
CY2013Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	1028000
CY2013Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	148604000
CY2013Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	128000
CY2013Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	841000
CY2013Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet
CY2013Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2954000
CY2013Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	153000
CY2013Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1254000
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	801000
CY2013Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	66794000
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due Future Minimum Sublease Rentals OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals	1883000
CY2013Q4	us-gaap	Assets Assets	71754000
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	68204000
CY2013Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	25058000
CY2013Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	2654000
CY2013Q4	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	340831000
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	5339000
CY2013Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	884000
CY2013Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	8500000
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	5311000
CY2013Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	1074000
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1948000
CY2013Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	145000
CY2013Q4	us-gaap	Assets Current AssetsCurrent	70297000
CY2013Q4	ziop	Estimated Fair Value Of Warrant EstimatedFairValueOfWarrant	3500000
CY2013Q4	ziop	Class Of Warrant Or Right Fair Value Assumption Risk Free Interest Rate ClassOfWarrantOrRightFairValueAssumptionRiskFreeInterestRate	0.0393	pure
CY2013Q4	ziop	Accrued Consulting Fees Current AccruedConsultingFeesCurrent	3751000
CY2013Q4	ziop	Deferred Tax Assets Capitalized Acquisition Costs DeferredTaxAssetsCapitalizedAcquisitionCosts	12323000
CY2013Q4	ziop	Class Of Warrant Or Right Fair Value Assumption Expected Life ClassOfWarrantOrRightFairValueAssumptionExpectedLife	7	Y
CY2013Q4	ziop	Deferred Tax Assets Depreciation DeferredTaxAssetsDepreciation	129000
CY2013Q4	ziop	Operating Leases Future Minimum Payments Due Net OperatingLeasesFutureMinimumPaymentsDueNet	2471000
CY2013Q4	ziop	Class Of Warrant Or Right Fair Value Assumption Expected Dividend Yield ClassOfWarrantOrRightFairValueAssumptionExpectedDividendYield	0.00	pure
CY2013Q4	ziop	Net Operating Loss Carryforward Excess Tax Deduction Related To Stock Based Compensation NetOperatingLossCarryforwardExcessTaxDeductionRelatedToStockBasedCompensation	4200000
CY2013Q4	ziop	Warrants Liability WarrantsLiability	11776000
CY2013Q4	ziop	Warrant Liabilities Fair Value Disclosure WarrantLiabilitiesFairValueDisclosure	11776000
CY2013Q4	ziop	Computer And Office Equipment Gross ComputerAndOfficeEquipmentGross	1076000
CY2013Q4	ziop	Accrued Preclinical Services Current AccruedPreclinicalServicesCurrent	513000
	us-gaap	Equity Issuance Dates EquityIssuanceDates	2003-09-09
	us-gaap	Net Income Loss NetIncomeLoss	-160000
CY2003Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	500000
CY2010Q2	us-gaap	Banking Fees And Commissions BankingFeesAndCommissions	2200000
CY2010Q2	ziop	Options To Purchase Common Stock OptionsToPurchaseCommonStock	1050000	shares
CY2010Q2	ziop	Net Proceeds From Issuance Of Common Stock NetProceedsFromIssuanceOfCommonStock	32800000
CY2010Q2	ziop	Common Stock Shares Sold CommonStockSharesSold	7000000	shares
CY2011Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	63500000
CY2011Q1	ziop	Common Stock Shares Sold CommonStockSharesSold	11040000	shares
CY2013Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	57600000
CY2013Q4	ziop	Common Stock Shares Sold CommonStockSharesSold	16445000	shares
CY2006Q2	us-gaap	Payments For Commissions PaymentsForCommissions	1700000
CY2006Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	37000000
CY2006Q2	ziop	Warrants To Purchase Aggregate Shares Of Common Stock WarrantsToPurchaseAggregateSharesOfCommonStock	799126	shares
CY2006Q2	ziop	Common Stock Exercise Price Per Share CommonStockExercisePricePerShare	5.56
CY2006Q2	ziop	Common Stock Shares Sold CommonStockSharesSold	7991256	shares
CY2006Q2	ziop	Term Of Warrants Issued To Investor TermOfWarrantsIssuedToInvestor	P5Y
CY2006Q2	ziop	Company Allocation Of Stock Units To Match Stock Unit Purchase CompanyAllocationOfStockUnitsToMatchStockUnitPurchase	0.30	pure
CY2004Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	251000
CY2004Q4	ziop	Warrants To Purchase Aggregate Shares Of Common Stock WarrantsToPurchaseAggregateSharesOfCommonStock	62621	shares
CY2004Q4	ziop	Related Party Transactions Fees Payable In Cash RelatedPartyTransactionsFeesPayableInCash	60000
CY2004Q4	ziop	Warrant Exercise Price WarrantExercisePrice	4.75
CY2006Q4	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	180000
CY2004Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4500000
CY2007Q1	us-gaap	Payments For Commissions PaymentsForCommissions	1000000
CY2007Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	30900000
CY2007Q1	ziop	Term Of Warrants TermOfWarrants	P5Y
CY2007Q1	ziop	Common Stock Purchase CommonStockPurchase	21244	shares
CY2007Q1	ziop	Common Stock Shares Sold CommonStockSharesSold	5910049	shares
CY2007Q1	ziop	Term Of Warrants Issued To Investor TermOfWarrantsIssuedToInvestor	P5Y
CY2007Q1	ziop	Company Allocation Of Stock Units To Match Stock Unit Purchase CompanyAllocationOfStockUnitsToMatchStockUnitPurchase	0.20	pure
CY2007Q1	ziop	Warrant Exercise Price WarrantExercisePrice	5.75
CY2005Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	18100000
CY2005Q2	ziop	Warrant Exercise Price As Percent Of Market Value WarrantExercisePriceAsPercentOfMarketValue	1.10	pure
CY2005Q2	ziop	Class Of Warrant Or Right Exercise Period ClassOfWarrantOrRightExercisePeriod	P7Y
CY2005Q2	ziop	Costs Reimbursed CostsReimbursed	50000
CY2005Q2	ziop	Aggregate Consideration Value Finalization Period After Closing AggregateConsiderationValueFinalizationPeriodAfterClosing	P3Y
CY2005Q3	us-gaap	Payments Of Distributions To Affiliates PaymentsOfDistributionsToAffiliates	425000
CY2007Q3	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	25111	shares
CY2007Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	104000
CY2007Q3	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	50000
CY2009Q3	us-gaap	Noninterest Expense Transfer Agent And Custodian Fees NoninterestExpenseTransferAgentAndCustodianFees	455000
CY2009Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5100000
CY2009Q3	ziop	Net Proceeds From Issuance Of Common Stock NetProceedsFromIssuanceOfCommonStock	4600000
CY2009Q3	ziop	Common Stock Shares Sold CommonStockSharesSold	2772337	shares
CY2009Q3	ziop	Placement Agents Warrant Percentage Of Shares Sold PlacementAgentsWarrantPercentageOfSharesSold	0.05	pure
CY2011Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	11600000
CY2011Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17500000
CY2011Q1	ziop	Common Stock Shares Sold CommonStockSharesSold	2426235	shares
CY2010Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	35000000
CY2010Q2	ziop	Common Stock Shares Sold CommonStockSharesSold	7000000	shares
CY2009Q4	us-gaap	Payments For Underwriting Expense PaymentsForUnderwritingExpense	2800000
CY2009Q4	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	48000000
CY2009Q4	ziop	Net Proceeds From Issuance Of Common Stock NetProceedsFromIssuanceOfCommonStock	45200000
CY2009Q4	ziop	Common Stock Shares Sold CommonStockSharesSold	15484000	shares
CY2010	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	6904	shares
CY2010	us-gaap	Net Income Loss NetIncomeLoss	-32670000
CY2010	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3637000
CY2010	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	1668000
CY2010	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	27000
CY2010	ziop	Class Of Warrant Or Right Exercised In Period ClassOfWarrantOrRightExercisedInPeriod	95505	shares
CY2010	ziop	Milestone Payment Under License Agreement MilestonePaymentUnderLicenseAgreement	0
CY2010	ziop	Stock Issued During Period Shares Stock Warrants Exercised StockIssuedDuringPeriodSharesStockWarrantsExercised	39225	shares
CY2010	ziop	Stock Issued During Period Value Stock Warrants Exercised StockIssuedDuringPeriodValueStockWarrantsExercised	121000
CY2005	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	1683000
CY2005	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4000
CY2005	us-gaap	Net Income Loss NetIncomeLoss	-9517000
CY2005	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	45000
CY2005	ziop	Stock Issued During Period Value Convertible Preferred New Issues StockIssuedDuringPeriodValueConvertiblePreferredNewIssues	15077000
CY2005	ziop	Warrants To Purchase Aggregate Shares Of Common Stock WarrantsToPurchaseAggregateSharesOfCommonStock	50000	shares
CY2005	ziop	Class Of Warrant Or Right Exercised In Period ClassOfWarrantOrRightExercisedInPeriod	12500	shares
CY2005	ziop	Convertible Preferred Stock Conversion Date ConvertiblePreferredStockConversionDate	2005-09-13
CY2005	ziop	Stock Issued Issuance Costs StockIssuedIssuanceCosts	1340000
CY2005	ziop	Stock Issued During Period Value Preferred Stock And Common Stock Warrants StockIssuedDuringPeriodValuePreferredStockAndCommonStockWarrants	1683000
CY2006	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	13092000
CY2006	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	25000
CY2006	us-gaap	Net Income Loss NetIncomeLoss	-17857000
CY2006	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2777000
CY2006	ziop	Class Of Warrant Or Right Cancelled In Period ClassOfWarrantOrRightCancelledInPeriod	37500	shares
CY2007	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	25111	shares
CY2007	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	5433000
CY2007	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	36000
CY2007	us-gaap	Net Income Loss NetIncomeLoss	-26608000
CY2007	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	120000
CY2009	us-gaap	Net Income Loss NetIncomeLoss	-7649000
CY2009	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2181000
CY2009	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	380000
CY2009	ziop	Warrants To Purchase Aggregate Shares Of Common Stock WarrantsToPurchaseAggregateSharesOfCommonStock	8206520	shares
CY2009	ziop	Stock Issued During Period Value Stock Warrants Exercised StockIssuedDuringPeriodValueStockWarrantsExercised	279000
CY2011	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	5.01
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	1894300	shares
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.8326	pure
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	2.85
CY2011	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34	pure
CY2011	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.65
CY2011	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.00	pure
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	229586	shares
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0269	pure
CY2011	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.00	pure
CY2011	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	3.56
CY2011	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.54	pure
CY2011	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	66003789	shares
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.04
CY2011	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.11	pure
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
CY2011	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-38835000
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0109	pure
CY2011	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	479666	shares
CY2011	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.06	pure
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	843083	shares
CY2011	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.01	pure
CY2011	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19206656	shares
CY2011	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.97
CY2011	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.04
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.52
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.8729	pure
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	16667	shares
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	848406	shares
CY2011	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	4000
CY2011	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1156000
CY2011	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	7583000
CY2011	us-gaap	Income Taxes Paid IncomeTaxesPaid
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y2M1D
CY2011	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0
CY2011	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	39000
CY2011	us-gaap	Interest Paid InterestPaid
CY2011	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	889000
CY2011	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
CY2011	us-gaap	Contracts Revenue ContractsRevenue	667000
CY2011	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	407000
CY2011	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	7583000
CY2011	us-gaap	Operating Income Loss OperatingIncomeLoss	-71400000
CY2011	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	274000
CY2011	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	79000
CY2011	us-gaap	Net Income Loss NetIncomeLoss	-63778000
CY2011	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	303000
CY2011	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2759000
CY2011	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
CY2011	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14984000
CY2011	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	84312000
CY2011	us-gaap	Share Based Compensation ShareBasedCompensation	2759000
CY2011	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	72067000
CY2011	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	273000
CY2011	us-gaap	Depreciation And Amortization DepreciationAndAmortization	268000
CY2011	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	44321000
CY2011	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	109000
CY2011	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	647000
CY2011	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
CY2011	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	38000
CY2011	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	0
CY2011	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	4333000
CY2011	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	12399000
CY2011	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	2759000
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	2500000
CY2011	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	8283000
CY2011	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	696000
CY2011	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0
CY2011	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	0
CY2011	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	980000
CY2011	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
CY2011	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2759000
CY2011	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1156000
CY2011	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	57083000
CY2011	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0
CY2011	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	17457000
CY2011	ziop	Class Of Warrant Or Right Exercised In Period ClassOfWarrantOrRightExercisedInPeriod	2516968	shares
CY2011	ziop	Effective Income Tax Rate Reconciliation Warrants EffectiveIncomeTaxRateReconciliationWarrants	0.04	pure
CY2011	ziop	Milestone Payment Under License Agreement MilestonePaymentUnderLicenseAgreement	0
CY2011	ziop	Effective Income Tax Rate Reconciliation Uncertain Tax Positions EffectiveIncomeTaxRateReconciliationUncertainTaxPositions	0.00	pure
CY2011	ziop	Stock Issued During Period Shares Stock Warrants Exercised StockIssuedDuringPeriodSharesStockWarrantsExercised	2377571	shares
CY2011	ziop	Effective Income Tax Rate Reconciliation Federal Research And Development Tax Grant EffectiveIncomeTaxRateReconciliationFederalResearchAndDevelopmentTaxGrant	0.00	pure
CY2011	ziop	Stock Issued During Period Value Stock Warrants Exercised StockIssuedDuringPeriodValueStockWarrantsExercised	12701000
CY2011	ziop	Proceeds From Issuance Of Common Stock And Warrants Net ProceedsFromIssuanceOfCommonStockAndWarrantsNet	71207000
CY2011	ziop	Issuance Of Warrants To Placement Agent In Public Offering IssuanceOfWarrantsToPlacementAgentInPublicOffering	0
CY2013	dei	Trading Symbol TradingSymbol	ZIOP
CY2013	dei	Entity Registrant Name EntityRegistrantName	ZIOPHARM ONCOLOGY INC
CY2013	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2013	dei	Amendment Flag AmendmentFlag	false
CY2013	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2013	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
CY2013	dei	Document Type DocumentType	10-K
CY2013	dei	Document Period End Date DocumentPeriodEndDate	2013-12-31
CY2013	dei	Entity Central Index Key EntityCentralIndexKey	0001107421
CY2013	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2013	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2013	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2013	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.58
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	2649900	shares
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.8340	pure
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	4.42
CY2013	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34	pure
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.28
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.00	pure
CY2013	us-gaap	Depreciation And Amortization DepreciationAndAmortization	738000
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	292399	shares
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0210	pure
CY2013	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.00	pure
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	4.31
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.46	pure
CY2013	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	85943175	shares
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.51
CY2013	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0501	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.09	pure
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-59509000
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P5Y11D
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0100	pure
CY2013	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	570168	shares
CY2013	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b><i>Concentrations of Credit Risk</i></b></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash accounts in commercial banks, which may, at times, exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash and cash equivalents.</p> </div>
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	2479732	shares
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.02	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.04	pure
CY2013	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17639935	shares
CY2013	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> <b><i>Use of Estimates</i></b></p> <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Although the Company regularly assesses these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.</p> <p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> The Company’s most significant estimates and judgments used in the preparation of our financial statements are:</p> <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt">  </p> <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td width="5%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">Clinical trial expenses;</td> </tr> </table> <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt">  </p> <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td width="5%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">Fair value measurements for stock based compensation and warrants; and</td> </tr> </table> <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt">  </p> <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td width="5%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">Income taxes.</td> </tr> </table> </div>
CY2013	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.66
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.68
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.34
CY2013	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-579000
CY2013	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y10M2D
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.9596	pure
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y11D
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	163747	shares
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	75272	shares
CY2013	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	-4000
CY2013	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	132000
CY2013	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	1185000
CY2013	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	956000
CY2013	us-gaap	Income Taxes Paid IncomeTaxesPaid
CY2013	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-585000
CY2013	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	600000
CY2013	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	800000
CY2013	us-gaap	Payments For Commissions PaymentsForCommissions	1700000
CY2013	us-gaap	Interest Paid InterestPaid
CY2013	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	26300000
CY2013	us-gaap	Long Term Purchase Commitment Amount LongTermPurchaseCommitmentAmount	50000000
CY2013	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	-37000
CY2013	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-4964000
CY2013	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
CY2013	us-gaap	Contracts Revenue ContractsRevenue	800000
CY2013	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-473000
CY2013	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	1185000
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-57713000
CY2013	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	498000
CY2013	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	87000
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-57107000
CY2013	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0
CY2013	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3507000
CY2013	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
CY2013	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15661000
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	54538000
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	3507000
CY2013	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	58513000
CY2013	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	498000
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-131000
CY2013	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-5102000
CY2013	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	625000
CY2013	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1000000
CY2013	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
CY2013	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	139000
CY2013	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	0
CY2013	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-800000
CY2013	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	200000
CY2013	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	3507000
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1400000
CY2013	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-10159000
CY2013	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1087000
CY2013	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	1000
CY2013	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	20000
CY2013	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	956000
CY2013	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
CY2013	us-gaap	Restructuring Charges RestructuringCharges	1700000
CY2013	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3507000
CY2013	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	42852000
CY2013	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0
CY2013	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0
CY2013	ziop	Term Of Warrants TermOfWarrants	P7Y
CY2013	ziop	Warrants To Purchase Aggregate Shares Of Common Stock WarrantsToPurchaseAggregateSharesOfCommonStock	799126	shares
CY2013	ziop	Class Of Warrant Or Right Exercised In Period ClassOfWarrantOrRightExercisedInPeriod	135346	shares
CY2013	ziop	Effective Income Tax Rate Reconciliation Warrants EffectiveIncomeTaxRateReconciliationWarrants	0.01	pure
CY2013	ziop	Milestone Payment Under License Agreement MilestonePaymentUnderLicenseAgreement	250000
CY2013	ziop	Minimum Percentage Of Purchase Committed Under Contract MinimumPercentageOfPurchaseCommittedUnderContract	0.1999	pure
CY2013	ziop	Effective Income Tax Rate Reconciliation Uncertain Tax Positions EffectiveIncomeTaxRateReconciliationUncertainTaxPositions	0.00	pure
CY2013	ziop	Class Of Warrant Or Right Issued In Period ClassOfWarrantOrRightIssuedInPeriod	184367	shares
CY2013	ziop	Stock Issued During Period Shares Stock Warrants Exercised StockIssuedDuringPeriodSharesStockWarrantsExercised	112808	shares
CY2013	ziop	Adjustments To Additional Paid In Capital Conversion Of Warrants AdjustmentsToAdditionalPaidInCapitalConversionOfWarrants	1700000
CY2013	ziop	Effective Income Tax Rate Reconciliation Federal Research And Development Tax Grant EffectiveIncomeTaxRateReconciliationFederalResearchAndDevelopmentTaxGrant	0.00	pure
CY2013	ziop	Percentage Of Net Proceeds Of Offering PercentageOfNetProceedsOfOffering	0.40	pure
CY2013	ziop	Placement Agents Warrant Percentage Of Shares Sold PlacementAgentsWarrantPercentageOfSharesSold	0.10	pure
CY2013	ziop	Stock Issued During Period Value Stock Warrants Exercised StockIssuedDuringPeriodValueStockWarrantsExercised	200000
CY2013	ziop	Warrant Exercise Price WarrantExercisePrice	5.09
CY2013	ziop	Expense Reimbursement ExpenseReimbursement	100000
CY2013	ziop	Proceeds From Issuance Of Common Stock And Warrants Net ProceedsFromIssuanceOfCommonStockAndWarrantsNet	53880000
CY2013	ziop	Issuance Of Warrants To Placement Agent In Public Offering IssuanceOfWarrantsToPlacementAgentInPublicOffering	0
CY2004	us-gaap	Net Income Loss NetIncomeLoss	-5687000
CY2004	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	251000
CY2004	ziop	Warrants To Purchase Aggregate Shares Of Common Stock WarrantsToPurchaseAggregateSharesOfCommonStock	62621	shares
CY2008	us-gaap	Net Income Loss NetIncomeLoss	-25231000
CY2008	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1600000
CY2012	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	5.70
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	2309650	shares
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.8336	pure
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	4.34
CY2012	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34	pure
CY2012	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.36
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.00	pure
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	351829	shares
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0113	pure
CY2012	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.00	pure
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	4.32
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.49	pure
CY2012	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	78546112	shares
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.06
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.10	pure
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-78832000
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0079	pure
CY2012	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	8300	shares
CY2012	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.05	pure
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	292533	shares
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.01	pure
CY2012	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19078496	shares
CY2012	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.22
CY2012	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	230000
CY2012	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	6050000
CY2012	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.61
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.39
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.8353	pure
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y3M11D
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	123370	shares
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	258032	shares
CY2012	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	43000
CY2012	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1559000
CY2012	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	6050000
CY2012	us-gaap	Income Taxes Paid IncomeTaxesPaid
CY2012	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-48000
CY2012	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-13000
CY2012	us-gaap	Interest Paid InterestPaid
CY2012	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	5599000
CY2012	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
CY2012	us-gaap	Contracts Revenue ContractsRevenue	800000
CY2012	us-gaap	Operating Income Loss OperatingIncomeLoss	-102169000
CY2012	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	546000
CY2012	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-21000
CY2012	us-gaap	Net Income Loss NetIncomeLoss	-96132000
CY2012	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	412000
CY2012	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4880000
CY2012	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
CY2012	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	19523000
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	48984000
CY2012	us-gaap	Share Based Compensation ShareBasedCompensation	4880000
CY2012	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	102969000
CY2012	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	546000
CY2012	us-gaap	Depreciation And Amortization DepreciationAndAmortization	658000
CY2012	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-31407000
CY2012	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	244000
CY2012	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1100000
CY2012	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
CY2012	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	266000
CY2012	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	0
CY2012	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-800000
CY2012	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	330000
CY2012	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	4880000
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	11000
CY2012	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	5695000
CY2012	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-218000
CY2012	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0
CY2012	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	0
CY2012	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	30000
CY2012	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
CY2012	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4880000
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1559000
CY2012	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	83446000
CY2012	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0
CY2012	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	18694000
CY2012	ziop	Class Of Warrant Or Right Exercised In Period ClassOfWarrantOrRightExercisedInPeriod	553914	shares
CY2012	ziop	Effective Income Tax Rate Reconciliation Warrants EffectiveIncomeTaxRateReconciliationWarrants	0.02	pure
CY2012	ziop	Milestone Payment Under License Agreement MilestonePaymentUnderLicenseAgreement	250000
CY2012	ziop	Effective Income Tax Rate Reconciliation Uncertain Tax Positions EffectiveIncomeTaxRateReconciliationUncertainTaxPositions	0.00	pure
CY2012	ziop	Stock Issued During Period Shares Stock Warrants Exercised StockIssuedDuringPeriodSharesStockWarrantsExercised	259660	shares
CY2012	ziop	Effective Income Tax Rate Reconciliation Federal Research And Development Tax Grant EffectiveIncomeTaxRateReconciliationFederalResearchAndDevelopmentTaxGrant	0.00	pure
CY2012	ziop	Stock Issued During Period Value Stock Warrants Exercised StockIssuedDuringPeriodValueStockWarrantsExercised	742000
CY2012	ziop	Proceeds From Issuance Of Common Stock And Warrants Net ProceedsFromIssuanceOfCommonStockAndWarrantsNet	49170000
CY2012	ziop	Issuance Of Warrants To Placement Agent In Public Offering IssuanceOfWarrantsToPlacementAgentInPublicOffering	0
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-281148000
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	128000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4758000
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	11956000
	us-gaap	Income Taxes Paid IncomeTaxesPaid
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-641000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4122000
	us-gaap	Interest Paid InterestPaid
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1948000
	us-gaap	Contracts Revenue ContractsRevenue	2267000
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	528000
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	11956000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-356909000
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	3364000
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	145000
	us-gaap	Net Income Loss NetIncomeLoss	-340831000
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	764000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	103979000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	354108000
	us-gaap	Share Based Compensation ShareBasedCompensation	23688000
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	359176000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3313000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	68204000
	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	1063000
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	5200000
	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	500000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	2733000
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	13278000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	6357000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	422000
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	2000
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	20000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2329000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4756000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	255197000
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	16760000
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	36151000
	ziop	Proceeds From Issuance Of Common Stock And Warrants Net ProceedsFromIssuanceOfCommonStockAndWarrantsNet	324605000
	ziop	Issuance Of Warrants To Placement Agent In Public Offering IssuanceOfWarrantsToPlacementAgentInPublicOffering	47276000
CY2012Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	52600000
CY2012Q1	ziop	Common Stock Shares Sold CommonStockSharesSold	10114401	shares
CY2009Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	48000000
CY2009Q4	ziop	Common Stock Shares Sold CommonStockSharesSold	15484000	shares
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.75
	us-gaap	Net Income Loss NetIncomeLoss	-15364000
CY2013Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.15
CY2013Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	10788000
CY2013Q1	us-gaap	Revenues Revenues	200000
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-23583000
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	-12799000
CY2013Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	23783000
CY2012Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.32
CY2012Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-5811000
CY2012Q1	us-gaap	Revenues Revenues	200000
CY2012Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-18633000
CY2012Q1	us-gaap	Net Income Loss NetIncomeLoss	-24470000
CY2012Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	18833000
CY2012Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.30
CY2012Q2	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-650000
CY2012Q2	us-gaap	Revenues Revenues	200000
CY2012Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-22966000
CY2012Q2	us-gaap	Net Income Loss NetIncomeLoss	-23613000
CY2012Q2	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	23166000
CY2013Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.22
CY2013Q2	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-403000
CY2013Q2	us-gaap	Revenues Revenues	200000
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-18296000
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	-18692000
CY2013Q2	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	18496000
CY2012Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.23
CY2012Q3	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	3945000
CY2012Q3	us-gaap	Revenues Revenues	200000
CY2012Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-21727000
CY2012Q3	us-gaap	Net Income Loss NetIncomeLoss	-17824000
CY2012Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	21927000
CY2013Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.20
CY2013Q3	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-7407000
CY2013Q3	us-gaap	Revenues Revenues	200000
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-9115000
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	-16713000
CY2013Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	9315000
CY2012Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.37
CY2012Q4	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	8566000
CY2012Q4	us-gaap	Revenues Revenues	200000
CY2012Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-38843000
CY2012Q4	us-gaap	Net Income Loss NetIncomeLoss	-30225000
CY2012Q4	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	39043000
CY2013Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.09
CY2013Q4	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-1793000
CY2013Q4	us-gaap	Revenues Revenues	200000
CY2013Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-6719000
CY2013Q4	us-gaap	Net Income Loss NetIncomeLoss	-8903000
CY2013Q4	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	6919000

Files In Submission

Name	View Source	Status
0001193125-14-080282-index-headers.html	Edgar Link	pending
0001193125-14-080282-index.html	Edgar Link	pending
0001193125-14-080282.txt	Edgar Link	pending
0001193125-14-080282-xbrl.zip	Edgar Link	pending
d672411d10k.htm	Edgar Link	pending
d672411dex231.htm	Edgar Link	pending
d672411dex311.htm	Edgar Link	pending
d672411dex312.htm	Edgar Link	pending
d672411dex321.htm	Edgar Link	pending
d672411dex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
g672411g66g20.jpg	Edgar Link	pending
g672411g69p81.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
ziop-20131231.xml	Edgar Link	completed
ziop-20131231.xsd	Edgar Link	pending
ziop-20131231_cal.xml	Edgar Link	unprocessable
ziop-20131231_def.xml	Edgar Link	unprocessable
ziop-20131231_lab.xml	Edgar Link	unprocessable
ziop-20131231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TCRT
Alaunos Therapeutics, Inc. Stock $tcrt

2014 Q1 Form 10-K Financial Statement

#000119312514080282 Filed on March 03, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TCRT Alaunos Therapeutics, Inc. Stock $tcrt

2014 Q1 Form 10-K Financial Statement

#000119312514080282 Filed on March 03, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TCRT
Alaunos Therapeutics, Inc. Stock $tcrt